Adjuvant combination reduces recurrence risk in early liver cancer
Click Here to Manage Email Alerts
Adjuvant therapy with atezolizumab and bevacizumab reduced recurrence risk compared with active surveillance for patients with certain types of early-stage liver cancer, according to topline data released by the agents’ manufacturer.
An estimated 70% to 80% of people with early-stage hepatocellular carcinoma experience disease recurrence after surgery.
The randomized phase 3 IMbrave050 study included 662 people with early-stage HCC at high risk for recurrence after resection or ablation with curative intent.
Researchers randomly assigned half of study participants to atezolizumab (Tecentriq, Genentech) — an anti-PD-L1 monoclonal antibody — dosed at 1,200 mg every 3 weeks, plus bevacizumab (Avastin, Genentech) — a humanized anti-VEGF monoclonal antibody — dosed at 15 mg/kg every 3 weeks. Treatment continued for a maximum 12 months.
The other half of study participants underwent active surveillance.
RFS assessed by independent review served as the primary endpoint. Secondary endpoints included OS, RFS per investigator assessment and RFS among patients with PD-L1-positive disease.
The study met its primary endpoint, with results of a prespecified interim analysis showing reduced risk for recurrence with the atezolizumab-bevacizumab combination.
OS data remained immature at data cutoff. Follow-up will continue until the next analysis.
The combination of atezolizumab and bevacizumab exhibited a safety profile consistent with prior reports of each agent.
Full results of IMbrave050 will be presented at a medical meeting.
“Today, more than 70% of people with early-stage HCC may have their cancer return after surgery, which is associated with poorer prognosis and shorter survival. IMbrave050 is the first phase 3 study to show that a cancer immunotherapy combination reduced the risk [for] disease returning in people with this type of HCC,” Levi Garraway, MD, PhD, chief medical officer and head of global product development for Genentech, said in a company-issued press release. “We are excited by the clinical benefit that this adjuvant Tecentriq combination may bring to people with early liver cancer and look forward to seeing more mature data to further confirm the benefit.”
Read more about
Click Here to Manage Email Alerts